Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that occupies a distinct position in the peptide research literature. Unlike most compounds studied solely in preclinical animal models, tesamorelin has been examined in registered human clinical trials, generating a body of published data that spans Phase 2 and Phase 3 research. This review summarizes the published findings, the mechanisms researchers have examined, and the tissue categories that have received the most attention in the literature.
Tesamorelin is a 44-amino acid synthetic peptide that mirrors the structure of endogenous GHRH, with the addition of a trans-3-hexenoic acid group at the N-terminus. This structural modification extends plasma stability compared to native GHRH, which has a very short half-life due to rapid DPP-IV cleavage. Also referred to as TH9507, the compound was developed by Theratechnologies and received FDA approval in 2010 under the brand name Egrifta — giving it a regulatory and clinical data profile unusual in the research peptide category.
The primary mechanism studied for tesamorelin is its binding to the GHRH receptor (GHRHR) — a G-protein coupled receptor expressed on somatotroph cells in the anterior pituitary gland. Upon binding, GHRHR activation initiates a cAMP-mediated signaling cascade that promotes both the synthesis and the pulsatile release of growth hormone. Researchers have noted that this mechanism produces a physiologically regulated pattern of GH secretion — pulsatile and subject to normal somatostatin feedback — which they contrast with the supraphysiological profiles produced by direct GH administration.
The most extensively studied application of tesamorelin is its relationship with visceral adipose tissue (VAT) — the metabolically active fat surrounding internal organs, distinct from subcutaneous fat. In a landmark Phase 3 randomized controlled trial published in the New England Journal of Medicine (Falutz et al., 2010), tesamorelin produced statistically significant reductions in VAT compared to placebo in subjects with HIV-associated lipodystrophy over 26 weeks. This 412-subject study used CT scan measurement of VAT as the primary endpoint — the methodological approach that formed the basis for FDA approval.
Falutz J, et al. Effects of tesamorelin on visceral adipose tissue and liver fat. J Acquir Immune Defic Syndr. 2010;53(3):311–322.
A 52-week extension study examined whether VAT reduction was maintained over a longer period, reporting continued maintenance in subjects who remained on tesamorelin, while subjects switched to placebo returned toward baseline — suggesting mechanism dependence rather than a durable structural change.
Insulin-like growth factor 1 (IGF-1) — a well-established downstream marker of GH axis activity — has been measured as a secondary endpoint in multiple tesamorelin trials. Published data consistently show IGF-1 elevation in tesamorelin-treated subjects compared to placebo, with levels generally remaining within normal physiological ranges for age and sex. Additional metabolic markers examined include triglyceride levels, waist circumference, and trunk-to-limb fat ratios.
More recent literature has examined tesamorelin in neurological contexts. A randomized controlled trial published in JAMA Psychiatry (Baker et al.) studied tesamorelin in older adults with mild cognitive impairment, reporting improvements in executive function and verbal memory scores compared to placebo at 20 weeks — findings the authors attributed to GH/IGF-1 axis modulation and downstream effects on hippocampal function.
Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment. Arch Neurol. 2012;69(11):1420–1429.
For informational purposes only. This content summarizes published research literature. Not medical advice, treatment recommendation, or dosing guidance.
